Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Endometrial Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Flow Cytometry 5Therapeutics 3Psychiatric Rehabilitation 3Methylprednisolone 3Immunologic Techniques 3Amplified Fragment Length Polymorphism Analysis 3Prednisone 2Polymerase Chain Reaction 2Ondansetron 2In Situ Hybridization, Fluorescence 2Immunoenzyme Techniques 2Gemcitabine 2Dexamethasone 2Calcium Dobesilate 2Aprepitant 2Analgesia 2Alemtuzumab 2sargramostim 1ruxolitinib 1rucaparib 1pemigatinib 1pembrolizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1aldesleukin 1abiraterone 1Vorinostat 1Voriconazole 1Valacyclovir 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × pemigatinib × Gynecologic × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡